CO2021007653A2 - Antagonistas - Google Patents

Antagonistas

Info

Publication number
CO2021007653A2
CO2021007653A2 CONC2021/0007653A CO2021007653A CO2021007653A2 CO 2021007653 A2 CO2021007653 A2 CO 2021007653A2 CO 2021007653 A CO2021007653 A CO 2021007653A CO 2021007653 A2 CO2021007653 A2 CO 2021007653A2
Authority
CO
Colombia
Prior art keywords
antagonists
pcsk9
antibodies
fragments
combinations
Prior art date
Application number
CONC2021/0007653A
Other languages
English (en)
Inventor
Allan Bradley
Qi Liang
E-Chiang Lee
Li-Ying Liou
Yu-Hui Huang
Yen-Ju Chen
Li-Tzu Chen
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of CO2021007653A2 publication Critical patent/CO2021007653A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a antagonistas de la proproteína convertasa subtilisina kexina tipo 9 (PCSK9), tales como anticuerpos y fragmentos, así como también a procedimientos, usos y combinaciones.
CONC2021/0007653A 2018-12-19 2021-06-10 Antagonistas CO2021007653A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820687.0A GB201820687D0 (en) 2018-12-19 2018-12-19 Antagonists
PCT/GB2019/053607 WO2020128467A2 (en) 2018-12-19 2019-12-18 Antagonists

Publications (1)

Publication Number Publication Date
CO2021007653A2 true CO2021007653A2 (es) 2021-09-30

Family

ID=65147244

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007653A CO2021007653A2 (es) 2018-12-19 2021-06-10 Antagonistas

Country Status (16)

Country Link
US (1) US20220049017A1 (es)
EP (1) EP3897830A2 (es)
JP (1) JP7522113B2 (es)
KR (1) KR20210105396A (es)
CN (1) CN113453756B (es)
AU (1) AU2019411526A1 (es)
BR (1) BR112021011886A2 (es)
CA (1) CA3122655A1 (es)
CO (1) CO2021007653A2 (es)
GB (1) GB201820687D0 (es)
IL (1) IL283413A (es)
MA (1) MA54534A (es)
MX (1) MX2021007448A (es)
SG (1) SG11202105784WA (es)
TW (1) TW202039565A (es)
WO (1) WO2020128467A2 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731568A (en) 1995-10-13 1998-03-24 Arctic Fox, Inc. Battery heating device and method
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
EP4215043A1 (en) 2009-07-08 2023-07-26 Kymab Limited Animal models and therapeutic molecules
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2650016A1 (en) * 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
KR102545770B1 (ko) 2012-04-20 2023-06-21 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
JP6267792B2 (ja) * 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
CN106062004A (zh) * 2013-12-17 2016-10-26 科马布有限公司 人靶标
US9017678B1 (en) * 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用

Also Published As

Publication number Publication date
CN113453756B (zh) 2024-08-02
MA54534A (fr) 2022-03-30
EP3897830A2 (en) 2021-10-27
GB201820687D0 (en) 2019-01-30
SG11202105784WA (en) 2021-07-29
JP7522113B2 (ja) 2024-07-24
MX2021007448A (es) 2021-12-10
JP2022514703A (ja) 2022-02-14
US20220049017A1 (en) 2022-02-17
WO2020128467A2 (en) 2020-06-25
WO2020128467A3 (en) 2020-07-23
CA3122655A1 (en) 2020-06-25
TW202039565A (zh) 2020-11-01
AU2019411526A1 (en) 2021-06-17
CN113453756A (zh) 2021-09-28
KR20210105396A (ko) 2021-08-26
IL283413A (en) 2021-07-29
BR112021011886A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
CY1123250T1 (el) Σταθερα σκευασματα τα οποια περιεχουν anti-pcsk9 αντισωματα
MX2023010757A (es) Variantes de proteasa y sus usos.
EA201391157A1 (ru) Антагонисты pcsk9
TR201906696T4 (tr) Pcsk9 antagoni̇stleri̇
MY168961A (en) Antibodies to pcsk9 and uses thereof
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201592215A1 (ru) Антисмысловые олигомеры и их конъюгаты, направленные на пропротеин конвертазу субтилизин/кексин типа 9 (pcsk9)
CO2017009061A2 (es) Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes
EA201791775A1 (ru) Цистеиновая протеаза
SG10201914126RA (en) Anti-ox40 antibodies and their uses
UY34063A (es) Métodos de tratamiento o prevención de trastornos relacionados con el colesterol
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
BR112020015308A8 (pt) Proteínas f de rsv estabilizadas e usos das mesmas
IL266066A (en) Methods for preventing cardiovascular events by reducing the protein proprotein convertase subtilisin kexin 9
CO2019009787A2 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
EA201892624A1 (ru) Растения, дающие бессемянные плоды
EA201690889A1 (ru) Режимы дозирования для применения ингибиторов pcsk9
HK1257102A1 (zh) 苯基哌嗪前蛋白轉化酶枯草桿菌蛋白酶/kexin9型(pcsk9)調節劑及其應用
MX2023003394A (es) Variantes de proteasa y sus usos.
CO2021007653A2 (es) Antagonistas
EA201990125A1 (ru) Антисмысловые олигомеры и их конъюгаты, направленные на пропротеин конвертазу субтилизин/кексин типа 9 (pcsk9)
EA201992593A1 (ru) Варианты сконструированной лигазы
EA202091666A1 (ru) Способ получения препаратов оил, обогащенных специфическими для опухолевых антигенов t-клетками
EP3341010A4 (en) MODULATION OF PROPROTEIN CONVERTASE SUBTILISINE / KEXINE 9 (PCSK9) EXPRESSION USING HSP27 AND / OR HSP25
EA201991343A1 (ru) Синтетические иммунные рецепторы и способы их применения